Ultragenyx Pharmaceutical Inc. (RARE)
| Market Cap | 2.61B -25.1% |
| Revenue (ttm) | 670.00M +13.5% |
| Net Income | -609.00M |
| EPS | -6.11 |
| Shares Out | 98.19M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 136,975 |
| Open | 26.38 |
| Previous Close | 26.30 |
| Day's Range | 26.01 - 26.77 |
| 52-Week Range | 18.29 - 42.37 |
| Beta | 0.39 |
| Analysts | Strong Buy |
| Price Target | 58.80 (+121.3%) |
| Earnings Date | May 5, 2026 |
About RARE
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment... [Read more]
Financial Performance
In 2025, Ultragenyx Pharmaceutical's revenue was $673.00 million, an increase of 20.18% compared to the previous year's $560.00 million. Losses were -$575.00 million, 1.05% more than in 2024.
Financial StatementsAnalyst Summary
According to 20 analysts, the average rating for RARE stock is "Strong Buy." The 12-month stock price target is $58.8, which is an increase of 121.30% from the latest price.
News
Ultragenyx price target lowered to $33 from $34 at Evercore ISI
Evercore ISI lowered the firm’s price target on Ultragenyx (RARE) to $33 from $34 and keeps an Outperform rating on the shares.
Ultragenyx price target lowered to $26 from $27 at Wedbush
Wedbush lowered the firm’s price target on Ultragenyx (RARE) to $26 from $27 and keeps a Neutral rating on the shares. While the top-line miss is disappointing, the firm looks…
Ultragenyx price target lowered to $43 from $52 at Guggenheim
Guggenheim lowered the firm’s price target on Ultragenyx (RARE) to $43 from $52 and keeps a Buy rating on the shares. The firm lowered its target to reflect challenges with…
Rare disease families find roadmap to drug development at bootcamps.
Ultragenyx's Rare Bootcamp is a multi-day forum that helps families learn about conducting rare disease research and the steps that go into developing a new drug.
Rare disease families find roadmap to drug development at bootcamps
Rare disease families are increasingly driving research efforts to find treatments for their children. Ultragenyx's Rare Bootcamp gives advocates a roadmap for navigating drug development.
Ultragenyx to Participate at Bank of America's 2026 Healthcare Conference
NOVATO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for seri...
Ultragenyx Pharmaceutical Earnings Call Transcript: Q1 2026
Q1 2026 revenue reached $136M, with strong growth in EVKEEZA and steady performance in CRYSVITA and DOJOLVI. 2026 revenue guidance is $730–$760M, with profitability targeted for 2027 and multiple new gene therapy launches anticipated.
Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update
First quarter total revenue of $136 million, Crysvita® revenue of $93 million and Dojolvi® revenue of $18 million
Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update
NOVATO, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for ser...
Ultragenyx price target lowered to $43 from $44 at Barclays
Barclays analyst Eliana Merle lowered the firm’s price target on Ultragenyx (RARE) to $43 from $44 and keeps an Overweight rating on the shares. The firm says the company’s valuation…
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NOVATO, Calif., April 24, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ra...
Ultragenyx price target raised to $67 from $50 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Ultragenyx (RARE) to $67 from $50 and keeps an Outperform rating on the shares. The firm, which applies a new probability-of-success framework…
DEADLINE NEXT WEEK: Berger Montague Advises Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Investors to Contact the Firm Before April 6, 2026
PHILADELPHIA, April 3, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) ...
Ultragenyx UX111 AAV9 biologics license application accepted for FDA review
Ultragenyx (RARE) announced the FDA has accepted for review the resubmitted biologics license application seeking accelerated approval for UX111 AAV9 gene therapy as a treatment for patients with Sanf...
Ultragenyx announces FDA clearance of UX016 investigational new drug application
Ultragenyx (RARE) announced that the FDA has cleared the investigational new drug application for UX016, an investigational small molecule prodrug of sialic acid being evaluated as a substrate replace...
Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy
Program to be externally funded by a venture philanthropy agreement through clinical proof-of-concept, including the Phase 1/2 study planned to begin in the second half of 2026 Program to be externall...
Ultragenyx downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst Salveen Richter downgraded Ultragenyx (RARE) to Neutral from Buy with a price target of $25, down from $61. The firm cites the miss of the setrusumab Phase…
Ultragenyx Facing Shareholder Lawsuit over Brittle Bone Disease Drug Claims
A class action lawsuit was filed against Ultragenyx Pharmaceutical ($RARE) on February 4, 2026. The federal securities class action alleges that plaintiffs acquired Ultragenyx stock at artificially in...
Ultragenyx's gene therapy helps control ammonia levels in late-stage study
Ultragenyx Pharmaceutical said on Thursday its experimental gene therapy helped patients in a late-stage trial to better control ammonia levels linked to a rare inherited disorder.
Ultragenyx Phase 3 Enh3ance study showed statistically significant results
Ultragenyx (RARE) Pharmaceutical announced positive results from its Phase 3 Enh3ance study of DTX301, an investigational AAV8 gene therapy for the treatment of ornithine transcarbamylase deficiency. ...
Ultragenyx price target lowered to $74 from $120 at JPMorgan
JPMorgan lowered the firm’s price target on Ultragenyx (RARE) to $74 from $120 and keeps an Overweight rating on the shares. At current share levels, the analyst sees no value…
Ultragenyx Pharmaceutical Transcript: Leerink Global Healthcare Conference 2026
Strong commercial growth supports a robust pipeline, with pivotal Angelman and gene therapy programs advancing toward key regulatory milestones. Angelman Phase 3 design addresses placebo effect, and gene therapy durability is supported by long-term data. GSDIa and Sanfilippo approvals are expected in the second half of the year.
Ultragenyx Pharmaceutical Transcript: Barclays 28th Annual Global Healthcare Conference
The company is advancing a diverse rare disease pipeline, with near-term regulatory decisions expected for GSD1A and Sanfilippo, and a pivotal Angelman phase III data readout anticipated in the second half of the year. Profitability is targeted for 2027, supported by a broad commercial footprint and robust late-stage programs.
Ultragenyx Pharmaceutical Transcript: TD Cowen 46th Annual Health Care Conference
Key updates include strong progress in Angelman syndrome trials, with Aspire phase III powered for cognition and MDRI endpoints, and Aurora supporting broader labeling. Setrusumab shows promise for bone disease with accelerated approval in view. Gene therapy programs advance despite regulatory delays, with launches for Sanfilippo and GSDIa prioritized.
Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud: Contact Berger Montague To Discuss Your Rights
Philadelphia, Pennsylvania--(Newsfile Corp. - February 24, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutic...